Clinical trial
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
NCT00006013 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006013 |
|---|---|
| Title | SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma |
| Official title | Phase II Trial of SU5416 as Treatment for Refractory/Relapsed Multiple Myeloma |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | semaxanib |
| Enrollment | 21 |
| Start date | Jun 1, 2000 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Jun 25, 2003 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: